Causaly, the AI company teaching computers to read, understand and interpret biomedical knowledge, is pleased to announce its series A fundraising round, which saw new and existing investors commit $4.8m into the company.
Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that UnitedHealthcare®, the largest commercial insurer in the United States, has lifted coverage restrictions on endobronchial valves, a minimally-invasive treatment option for severe emphysema, a form of COPD.
The Sheikh Shakhbout Medical City (SSMC), one of the 10 largest hospitals in the United Arab Emirates (UAE), opened its doors recently, marking the completion of a 10-year, 3.2-million square foot project.
Nihon Kohden, a U.S. market leader in precision medical products and services, today announced the launch of its new NKV-550 Series Ventilator System that offers a full suite of applications necessary in a critical care setting for patients of all ages – from neonate through adult.
Kinsa, a public health company on a mission to help individuals and communities stop the spread of infectious illness, today announced the release of its new feature-rich smartphone app (available on both iOS and Android) in preparation for this year's flu season.
Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza® Omnia™ Spinal Cord Stimulation (SCS) System.
Okami Medical Inc., a medical device company, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and initial launch of the LOBOTM Vascular Occlusion System.
Masimo announced today that Radius Capnography™, a portable real-time capnograph with wireless Bluetooth® connectivity, has received CE marking.
CoreLink, LLC, a leading designer and manufacturer of spinal implant systems, today announced the introduction of the Oro™ Lateral Plate System designed for optimum versatility to treat patients suffering from degenerative disk disease, spondylolisthesis, trauma, or spinal deformities.
“This important study will help inform us of the potential impact of clot removal in patients with high thrombus burden,” said Larry J. Diaz-Sandoval, M.D., director, endovascular research and interventions, Metro Health-University of Michigan Health Hospital, Grand Rapids, Michigan, whose team enrolled the first patient in the CHEETAH study.